

## **RARE DISEASE COLLABORATIVE NETWORK HEREDITARY GASTROINTESTINAL POLYPOSIS SYNDROMES**

### **CONSENSUS STATEMENT AGREED AT RDCN MEETING BIRMINGHAM 17<sup>TH</sup> FEBRUARY 2022**

#### **Background**

NHS England set out in the *Implementation Plan for the UK Strategy for Rare Diseases* that it would develop and implement Rare Disease Collaborative Networks (RDCNs), with the definition of a RDCN being a 'recognised network of member providers, each of which has demonstrable research-active interest in a rare/very rare disease, the aim of the network being to improve patient outcomes'. The network is composed of Rare Disease Collaborative Centres. A Rare Disease Collaborative Centre (RDCC) is a 'provider that has been recognised as having a demonstrable research-active interest in a rare/very rare disease and who works with other recognised providers in a network to improve patient outcomes'.

This initiative is also in line with the NHS England Board paper '12 Actions to Support and Apply Research in the NHS' discussed on 30 November 2017.

#### **Conditions covered**

- Familial adenomatous polyposis
- MutYH-associated polyposis
- Polymerase proofreading associated polyposis
- Peutz-Jeghers syndrome
- Juvenile polyposis syndrome
- Other ultra-rare Mendelian polyposis syndromes

#### **Rare Disease Collaborative Centres and Network**

The following centres are now recognised by NHSE:

- Birmingham
- Edinburgh
- Manchester
- St Mark's Hospital, London

Each of these Centres has demonstrated compliance with commitment 24 of the UK Strategy for Rare Diseases:

- Has a sufficient caseload to build recognised expertise
- Service does not rely on a single clinician
- Co-ordinates care
- Arranges for co-ordinated transition from children's to adult services
- Involves people with the rare disease, and their families and carers
- Supports research activity

Additional Centres complying but awaiting recognition:

- Cardiff
- Southampton
- South West/Peninsula

### **Principles of clinical care**

Patients and families with an hereditary gastrointestinal polyposis syndrome need lifelong care and support, with personalised key clinical decisions including around:

- Type and timing of colorectal surgery to prevent bowel cancer
- Intestinal endoscopic surveillance programmes according to disease severity and underlying genetic cause of disease
- Requirement for extra-intestinal surveillance. Patients with these conditions require lifelong care
- Cascade genetic testing and surveillance of family members
- Family planning/pre-implantation genetic diagnosis

### **Current situation**

Currently the majority of patients and families with an hereditary gastrointestinal polyposis syndrome have care locally under non-specialists, often non-compliant with current guidelines, without sufficient experience and without offering access to research. Countless examples can be provided of suboptimal care when patients are managed outside of a structured, multidisciplinary polyposis service.

This continues despite the existence of centres of excellence, national and international guidelines, and published evidence demonstrating that outcomes are significantly improved by care in a specialist centre with dedicated call-up arrangements.

### **Future provision of care**

We believe that the current inequality in access to care and research is best addressed by development of the RDCN consisting of RDCC's providing high quality specialist care, with consistent adherence to national evidence-based guidelines and standards, and collaborating in research.

Eventually all patients and families with an hereditary gastrointestinal polyposis syndrome should have their care delivered by one of these centres, with local pathways being developed to facilitate referral and patient data management systems/registries being put in place to allow effective recall, standardisation of data collection and monitoring of agreed KPI's.

Until sufficient resource has been established within the RDCN to accommodate all patients, it is acceptable that aspects of their care (eg genetic testing, risk reduction surgery, endoscopic surveillance) be provided outside of the network, provided that current guidelines are followed and these key aspects are discussed and documented at the MDT of one of RDCC's:

- Timing and type of risk reduction surgery
- Endoscopic management of polyps
- Management of extra-intestinal manifestations

Signed by



Prof Sue Clark, Chair on behalf of the attendees

St Mark's Hospital, London:

Prof Sue Clark (consultant colorectal surgeon)  
Vicky Cuthill (polyposis nurse practitioner)  
Jackie Hawkins (paediatric polyposis nurse practitioner)  
Dr Warren Hyer (consultant paediatric gastroenterologist)  
Dr Andy Latchford (consultant gastroenterologist)  
Mr Ashish Sinha (consultant colorectal surgeon)

Edinburgh:

Miss Farhat Din (consultant colorectal surgeon)

Birmingham:

Prof Andrew Beggs (consultant colorectal surgeon)  
Mr Anant Desai (consultant plastic surgeon)  
Prof Dion Morton (consultant colorectal surgeon)

Manchester:

Debbie Hitchen (colorectal clinical nurse specialist)  
Prof James Hill (consultant colorectal surgeon)  
Dr Fiona Lalloo (consultant clinical geneticist)  
Miss Katy Newton (consultant colorectal surgeon)  
Sarah Pugh (genetic counsellor)

Cardiff:

Dr Sunil Dolwani (consultant gastroenterologist)  
Miss Rachel Hargest (consultant colorectal surgeon)  
Mr James Horwood (consultant colorectal surgeon)  
Dr Raji Ramaraj (consultant gastroenterologist)  
Dr Mark Rogers (consultant clinical geneticist)

Liverpool:

Dr Paul Collins (consultant gastroenterologist)  
Miss Frances McNichol (consultant colorectal surgeon)

Southampton:

Mr Nicholas Beck (consultant colorectal surgeon)  
Dr Lucy Side (consultant clinical geneticist)

South West/Peninsula:

Mr Frank McDermott (consultant colorectal surgeon)